Correcting metabolic abnormalities may help lessen urinary problems
2014-12-08
(Press-News.org) Metabolic syndrome is linked with an increased frequency and severity of lower urinary tract symptoms, but weight loss surgery may lessen these symptoms. The findings, which come from two studies published in BJU International, indicate that urinary problems may be added to the list of issues that can improve with efforts that address altered metabolism.
Lower urinary tract symptoms related to urinary frequency and urgency, bladder leakage, the need to urinate at night, and incomplete bladder emptying are associated with obesity in both men and women. To see if these symptoms might also be linked with metabolic syndrome (a cluster of abnormalities including hypertension, high cholesterol, high blood glucose levels, and abdominal obesity), François Desgrandchamps, MD, PhD, of Saint-Louis Hospital in France, and his colleagues analyzed information on 4666 male patients aged 55 to 100 years who consulted a general practitioner during a 12-day period in 2009. Metabolic syndrome was reported in 51.5 percent of the patients and 47 percent were treated for lower urinary tract symptoms. There was a significant link between metabolic syndrome and treated lower urinary tract symptoms. The risk to be treated for lower urinary tract symptoms also increased with increasing number of metabolic syndrome components. Also, among individuals with lower urinary tract symptoms, symptoms were more severe in those with metabolic syndrome. "The prevention of such modifiable factors by the promotion of dietary changes and regular physical activity practice may be of great interest for public health," the authors concluded.
In another study, researchers in New Zealand looked to see if weight loss, or bariatric, surgery in obese individuals might lessen lower urinary tract symptoms. It's known that such surgery leads to improvement or even resolution of a growing list of health problems commonly associated with obesity such as type 2 diabetes, hypertension, and sleep apnea. The investigators studied 72 patients who underwent the surgery and were followed for one year. There was significant weight loss and a reduction of body mass index after surgery. At six weeks, a significant reduction in overall symptoms was noted, and this improvement was sustained at one year. Also, insulin sensitivity improved, indicating a lessening of individuals' risk for developing type 2 diabetes.
"Interestingly, in our study, improvements in lower urinary tract symptoms were generally seen soon after surgery, and they did not seem to be related to the time course or degree of weight loss," said co-author Richard Stubbs, MD, FRCS, FRACS, of Wakefield Hospital. "Rather, there is an indication that the improvement in the urinary symptoms is linked to improvements in insulin resistance, which are now known to occur almost immediately following bariatric surgery."
The investigators noted that it is not a surprise that many symptoms and medical problems associated with obesity improve when weight loss occurs. "What has been a surprise and what is potentially so important is that so many problems, including issues related to urinary function, improve so quickly after bariatric surgery, even before great weight loss has occurred," said senior author Andrew Kennedy-Smith, FRACS, of Wellington Hospital. "The relationship we have found between these symptoms and insulin resistance is of considerable potential importance. This finding calls into question our fundamental understanding of why these problems arise, and therefore how they might best be treated." Traditional thinking suggests that obesity leads to insulin resistance, but perhaps insulin resistance is itself a major cause of obesity. Therefore, developing effective treatments for insulin resistance may help address a whole raft of conditions, including lower urinary tract symptoms.
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2014-12-08
HANOVER, N.H. - December 8, 2014 - With health systems in the U.S., U.K., and around the world trying to increase vaccination levels, it is critical to understand how to address vaccine hesitancy and counter myths about vaccine safety. A new article in the journal "Vaccine" concludes, however, that correcting myths about vaccines may not be the most effective approach to promoting immunization among vaccine skeptics. The study, which was co-authored by Brendan Nyhan, an assistant professor of government at Dartmouth College, and Jason Reifler, a senior lecturer of politics ...
2014-12-08
SAN FRANCISCO - The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition. Highlights of the new trial results will include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and ...
2014-12-08
Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).
The study suggests that attacking those subsets with targeted drugs may degrade the disease's ability to spread throughout the bone marrow of affected patients, the authors say.
The discovery was made by developing a mouse model of the disease that enabled researchers ...
2014-12-08
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.
Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.
The phase 2 multicenter trial was the first ...
2014-12-08
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast) cells in the blood and/or bone marrow. Higher-risk patients experience an unusually large percentage of blasts in their blood. Patients ...
2014-12-07
HOUSTON - (Dec. 7, 2014) - An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease.
"It is widely thought amongst the clinical community that there is no association between family history and development of glioma. Because we know very little about the contributing genetic factors, when cases occur in two or more family ...
2014-12-07
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
The study, led by Farhad Ravandi, M.D, professor of medicine, department of leukemia at The University of Texas MD Anderson Cancer Center, demonstrated increased survival rates, particularly in AML patients over age 60.
Ravandi's study results were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) annual conference in San Francisco and ...
2014-12-07
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
The intergroup trial, presented at the 56th annual meeting of the American Society of Hematology, enrolled 296 adolescent and young adult patients with ALL. All participants were treated by adult hematologists-oncologists on a pediatric protocol, including four ...
2014-12-07
SAN FRANCISCO (DECEMBER 7, 2014) - Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.
The trial's data were presented by study authors Leslie Lehmann, MD, ...
2014-12-07
(SAN FRANCISCO, DECEMBER 7, 2014) - Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
In recent years, outcomes for patients with leukemia have steadily improved with the emergence of numerous therapies that target specific genetic drivers of disease, ...
LAST 30 PRESS RELEASES:
[Press-News.org] Correcting metabolic abnormalities may help lessen urinary problems